Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4260252 | 0.82 | HMGCR (0.33) | HMGCRPOLBKMT2AATM | |
| SCHEMBL15970638 | 0.79 | KDM4E (0.31) | POLB | |
| SCHEMBL15643139 | 0.77 | KMT2A (0.36) | MGLLKMT2AATM | |
| SCHEMBL1245548 | 0.77 | MMP1 (0.36) | MGLLKMT2AATM | |
| SCHEMBL15970691 | 0.77 | CTSA (0.31) | POLBMGLL | |
| SCHEMBL17155176 | 0.76 | MAPK1 (0.35) | MGLLKMT2AATM | |
| SCHEMBL16310469 | 0.74 | KMT2A (0.37) | MGLLKMT2AATM | |
| SCHEMBL19704975 | 0.74 | MGLL (0.35) | MGLLKMT2AATM | |
| SCHEMBL11267463 | 0.74 | KMT2A (0.34) | MGLLKMT2AATM | |
| SCHEMBL12741112 | 0.73 | ELANE (0.37) | MGLLKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1239886-B1 | LABELLED ASCORBIC ACID DERIVATIVES | GE HEALTHCARE LTD (GB) | 2006-11-29 | — | — | EP | disclosed |
| US-6749832-B2 | DIAGNOSIS, PROGNOSIS AND RADIOTHERAPY OF METASTATIC BONE DISEASE; SUCH AS TAGGED 5-(2-AMINO-1-HYDROXYETHYL)-3,4-DIBENZYLOXY-5H-FURAN-2-ONE | AMERSHAM PLC (GB) | 2004-06-15 | — | — | US | disclosed |
| US-20030153736-A1 | Labelled ascorbic acid derivatives | GE HEALTHCARE LIMITED (GB) | 2003-08-14 | — | — | US | disclosed |
| EP-1239886-A2 | LABELLED ASCORBIC ACID DERIVATIVES | GE Healthcare Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001047564-A2 | LABELLED ASCORBIC ACID DERIVATIVES | AMERSHAM PLC (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153736-A1 | Labelled ascorbic acid derivatives | CYP27B1, CYP24A1, XDH | HMGCR 240/4885POLB 2675/4885MGLL 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.